The efficacy of abatacept focusing on anti-CCP antibody in Japanese patients with rheumatoid arthritis for 104 weeks

Takeshi MochizukiDepartment of Orthopaedic Surgery, Kamagaya General Hospital, Japan; Correspondence[email protected]

Koichiro YanoInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan;

Katsunori IkariInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan;

Ryo HiroshimaDepartment of Orthopaedic Surgery, Kamagaya General Hospital, Japan;

Kosei KawakamiDepartment of Orthopaedic Surgery, Kamagaya General Hospital, Japan;

Naoko KoenumaDepartment of Orthopaedic Surgery, Kamagaya General Hospital, Japan;

Mina IshibashiDepartment of Orthopaedic Surgery, Kamagaya General Hospital, Japan;

Shigeki MomoharaDepartment of Orthopaedic Surgery, Keio University, Tokyo, Japan

show all

References

Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:491–8.
PubMed Web of Science ®Google Scholar
Mochizuki T, Yano K, Ikari K, Hiroshima R, Takaoka H, Kawakami K, et al. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice. Mod Rheumatol. 2016;26:499–506.
PubMed Web of Science ®Google Scholar
Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75:709–14.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The efficacy of abatacept focusing on anti-CCP antibody in Japanese patients with rheumatoid arthritis for 104 weeks

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The efficacy of abatacept focusing on anti-CCP antibody in Japanese patients with rheumatoid arthritis for 104 weeks

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date